Small molecules are chemical entities with the size of about 500 Da and with additional drug-like chemical and physical properties. These type of molecules is an important part in the arsenal of therapeutics. The discovery of small molecules targeting PPIs is a challenging scientific path. Unlike enzymes, PPIs have a large and shallow interface and do not result in an outcome assay. Among the different approached for the discovery of small molecules targeting specific protein, the integration of computational and biophysical tools is a promising path to the discovery of PPI inhibitors.

A different approach to modulate protein-protein interactions is to rely on nature itself. For that purpose, one of the partner proteins or a fragment (peptide) of it can be further optimized using lab-evolution tools. These entities are much larger than the former small molecules where peptides range 1-5 kDa and protein are usually larger than 10 kDa.

Some optimized proteins interfering with PPIs show better activity profile than antibodies and thus pose a promising therapeutic path.

​

Design-specific molecules and optimized peptides for inhibition of the PHD protein which enhances collagen production in cells.

1. Discovery of small molecules targeting new Protein-Protein interactions

2. Design of anti-inflammation and anti-fungal optimized peptides for wide range of applications.

3. New immune-suppression solutions targeting the calineurin-NFAT interaction

4. Developing an optimized proteins as Triple-Negative Breast Cancer markers for MRI applications

5. Optimized proteins as a novel non-antibody biologic immunotherapy drug